Analysis Of EGFR Mutation And Mutation Abundance In Prognosis Of Non - Small Cell Lung Cancer In Guangxi

EGFR MUTATION STATUS OF NON-SMALL CELL LUNG CANCER IN HAN AND ETHNIC MINORITIES IN THE GUANGXI PROVINCE OF CHINAObjective:The EGFR mutation affected the efficancy of target-therapy on non-small cell lung cancer. The NSCLC EGFR mutation status in minority populations is still unknown. This study aims to analysis the status of EGFR mutation in the Chinese population focusing on the difference between Han and ethnic minorities in the Guangxi region of China.Methods:We continuously collected 1062 sample in tumor hospital affiliated Guangxi Medcial University from August first 2010 to April 31, 2015. We collected the formalin fixed paraffin embedded tissue or the fresh/frozen tissue. The 29 mutation types were detection by ARMS-PCR.Result:The NSCLC overall rate of EGFR mutation in Guangxi was 39.4%. The rate on Han, Zhuang, Yao, Mulao and other minorities were 38.3% (306/799),43.3%(97/224),27.8%(5/18),66.7%(6/9) and 33.3%(4/12), respectively. The rate of EGFR mutation show no statistical difference on the different races studied (P= 0.211). There were 6 cases seen in 9 Mulao patients in this cohort. The EGFR mutation subtypes show no significant distribution difference on Han and Zhuang populations (P=0.088). The EGFR mutation was more frequent on older (>65 years) males of Zhuang origin but no significant difference between age and EGFR mutation on gender was evident in the Han population.Conclusion:There was no significantly difference of EGFR mutation between the Zhuang and Han ethnic in Guangxi.A COMPARISON OF PROGNOSTIC ANALYSIS BETWEEN EGFR 19-del AND L858R MUTATIONS IN NON-SMALL CELL LUNG CANCER PATIENTSObjective:To study the difference of prognosis betwween exon 19 deletion mutation (19-del) and exon 21 L858R point mutation on non-small cell lung cancer patients who harbored EGFR mutations.Methods:We continuous collected 257 cases of non small cell lung cancer patients who harbored 19-del or L858R mutations from September 1,2010 to 31 December 2013, the affiliated tumor hospital of guangxi medical university. All paitients were diagonosis by histopathology. The EGFR mutation were detected by ARMS-PCR. Then collected clinical data, regular follow-up to death what is the end point events. All the data analysis were conducted in SPSS 17.0 software. This retrospective study was supported by affiliated tumor hospital of guangxi medical university.Result:There were 134 cases harbored 19-del mutation and 123 cases harbored L858R mutation in 257 patients. The median age was 58 years. The two groups of patients show no statistical difference in gender, age, nationality, histological subtypes, differentiation, TNM staging and clinical staging (P>0.05). The survival analysis show that the median survival time were 798 days and 710 days in groups of 19-del mutation and L858R mutation, separately. The overall survival time showed no statistical difference in this two groups (P>0.05). Subsequently, we conducted an stratified analysis and the result revealed that the group of 19-del mutation show a longer overall survival time than L858R mutation cases in patients of Han (P=0.047). But we can’t observed this difference in patients of Zhuang (P>0.05). Meanwhile, the overall survival time showed no statistically difference in age, gender, TNM staging and clinical staging between 19-del and L858R mutation (P>0.05).Conclusion:These two kinds of mutation subtypes have no difference in clinical characteristic and overall survival time as a whole. However, the interesting finding was that the cases harbored 19-del mutation show a better prognosis than the cases who harbored L858R mutation in Han patients.THE MUTATION ABUNDANCE AFFECTS THE TARGETED THERAPY EFFICANCY ON NSCLC PATIENTS WHO HARBORED L858R MUTATIONObjective:to explore the mutation abundance affect the targeted therapy efficancy on non-small-cell lung cancer patients who harbored L858R mutation subtype.Methods:We continuous collected non-small cell lung cancer patients who harbored L858R mutations from September 1,2010 to 31 December 2013, the affiliated tumor hospital of guangxi medical university. Exclude the patients who don’t take targeted therapy or don’t have complet follow-up data. The gene copies of sample DNA were assess by droplit digital PCR. The mutation types were marked by FAM, and the wild types were marked by VIC. The propotion of the mutation copies in the reaction were defined as the abandence of mutation. The progress-free survival were calculated from the first day that the patients take EGFR-TKIs, and ending with desease progression. The survival analysis were assessed by K-M curve method. All data statistic were conducted in SPSS 17.0.Result:There were 8 cases according with the inclusion criteria in this study, the survival analysis demaonstrated that there were no significant statistical difference of the PFS in the patients with difference mutation abandence.Conclusion:Small sample analysis on NSCLC patients who with L858R mutations revealed that the abundance of mutatation may affected the PFS of target therapy.